Now, before you get all up in arms and say, "how can you even think about supporting a middle eastern terrorist group?!", let me explain. First of all, I'm not talking about ISIS the Islamic state now known as IS, I will be discussing and analyzing the stock of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS). It is just unfortunate that they happen to have the same name. Yesterday, there was a major trend change signal in ISIS Pharmaceuticals. This signal indicated that the trend had reversed to the upside and a long position was now warranted. Technically, the stock looks very good and capable of moving another 10% to 15% higher from current levels. To learn more about how you can take advantage of the situation in the stock of of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), check out today's video. Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) was founded in 1989 and is headquartered in Carlsbad, California.
You are now leaving a Magnifi Communities’ website and are going to a website that is not operated by Magnifi Communities. This website is operated by Magnifi LLC, an SEC registered investment adviser affiliated with Magnifi Communities.
Magnifi Communities does not endorse this website, its sponsor, or any of the policies, activities, products, or services offered on the site. We are not responsible for the content or availability of linked site.